Microsize antibodies for $99 | Learn More >>

Product listing: Helios (D8W4X) XP® Rabbit mAb (Alexa Fluor® 488 Conjugate), UniProt ID Q9UKS7 #56424 to IFN-β1 (D1D7G) Rabbit mAb, UniProt ID P01574 #73671

$348
50 tests
100 µl
This Cell Signaling Technology antibody is conjugated to Alexa Fluor® 488 fluorescent dye and tested in-house for direct flow cytometry analysis in human cells. The antibody is expected to exhibit the same species cross-reactivity as the unconjugated Helios (D8W4X) XP® Rabbit mAb #42427.
APPLICATIONS
REACTIVITY
Human, Mouse

Application Methods: Flow Cytometry

Background: Helios (Ikaros family zinc finger 2, IZKF2) is an Ikaros family transcription factor composed of several zinc fingers that mediate DNA binding and homodimerization or heterodimerization with other Ikaros family proteins (1,2). In the hematopoietic system, Helios expression is restricted to T cells and early hematopoietic progenitors (1,2). In regulatory T cells, expression of Helios contributes to an anergic phenotype by binding to the IL-2 promoter and suppressing IL-2 transcription (3). In addition, alteration of the corresponding Helios gene IZKF2 is one hallmark of low-hypodiploid acute lymphoblastic leukemia (4).

$348
50 tests
100 µl
This Cell Signaling Technology antibody is conjugated to Alexa Fluor® 647 fluorescent dye and tested in-house for direct flow cytometric analysis in human cells. The antibody is expected to exhibit the same species cross-reactivity as the unconjugated Helios (D8W4X) XP® Rabbit mAb #42427.
APPLICATIONS
REACTIVITY
Human, Mouse

Application Methods: Flow Cytometry

Background: Helios (Ikaros family zinc finger 2, IZKF2) is an Ikaros family transcription factor composed of several zinc fingers that mediate DNA binding and homodimerization or heterodimerization with other Ikaros family proteins (1,2). In the hematopoietic system, Helios expression is restricted to T cells and early hematopoietic progenitors (1,2). In regulatory T cells, expression of Helios contributes to an anergic phenotype by binding to the IL-2 promoter and suppressing IL-2 transcription (3). In addition, alteration of the corresponding Helios gene IZKF2 is one hallmark of low-hypodiploid acute lymphoblastic leukemia (4).

$348
50 tests
100 µl
This Cell Signaling Technology antibody is conjugated to phycoerythrin (PE) and tested in-house for direct flow cytometry analysis in human cells. This antibody is expected to exhibit the same species cross-reactivity as the unconjugated Helios (D8W4X) XP® Rabbit mAb #42427.
APPLICATIONS
REACTIVITY
Human, Mouse

Application Methods: Flow Cytometry

Background: Helios (Ikaros family zinc finger 2, IZKF2) is an Ikaros family transcription factor composed of several zinc fingers that mediate DNA binding and homodimerization or heterodimerization with other Ikaros family proteins (1,2). In the hematopoietic system, Helios expression is restricted to T cells and early hematopoietic progenitors (1,2). In regulatory T cells, expression of Helios contributes to an anergic phenotype by binding to the IL-2 promoter and suppressing IL-2 transcription (3). In addition, alteration of the corresponding Helios gene IZKF2 is one hallmark of low-hypodiploid acute lymphoblastic leukemia (4).

$122
20 µl
$293
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse

Application Methods: Chromatin IP, Chromatin IP-seq, Flow Cytometry, Immunoprecipitation, Western Blotting

Background: Helios (Ikaros family zinc finger 2, IZKF2) is an Ikaros family transcription factor composed of several zinc fingers that mediate DNA binding and homodimerization or heterodimerization with other Ikaros family proteins (1,2). In the hematopoietic system, Helios expression is restricted to T cells and early hematopoietic progenitors (1,2). In regulatory T cells, expression of Helios contributes to an anergic phenotype by binding to the IL-2 promoter and suppressing IL-2 transcription (3). In addition, alteration of the corresponding Helios gene IZKF2 is one hallmark of low-hypodiploid acute lymphoblastic leukemia (4).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse

Application Methods: IHC-Leica® Bond™, Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blotting

Background: Helios (Ikaros family zinc finger 2, IZKF2) is an Ikaros family transcription factor composed of several zinc fingers that mediate DNA binding and homodimerization or heterodimerization with other Ikaros family proteins (1,2). In the hematopoietic system, Helios expression is restricted to T cells and early hematopoietic progenitors (1,2). In regulatory T cells, expression of Helios contributes to an anergic phenotype by binding to the IL-2 promoter and suppressing IL-2 transcription (3). In addition, alteration of the corresponding Helios gene IZKF2 is one hallmark of low-hypodiploid acute lymphoblastic leukemia (4).

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Western Blotting

Background: HERV-H LTR-associating protein 2 (HHLA2, with alternative names of B7-H5 and B7-H7) is a member of the B7 immunoglobulin superfamily (1). HHLA2 protein is constitutively expressed on the surface of human monocytes and is induced on B cells after stimulation with LPS and IFN-γ (1,2). Through interaction with TMIGD2, which is constitutively expressed on all naïve T cells and the majority of natural killer cells, but not on T regulatory cells or B cells, HHLA2 co-stimulates T cells in the context of TCR-mediated activation, enhancing T cell proliferation and cytokine production via an AKT-dependent signaling cascade (2). Contrary to this, HHLA2 has also been shown to inhibit T cell proliferation and cytokine production, suggesting a secondary receptor for HHLA2 that is expressed on activated T cells with co-inhibitory functions (3). Moreover, HHLA2 has been shown to be highly expressed in various types of cancer, and is associated with a poor prognosis (4-10). Further understanding the immunologic functions of the HHLA2 pathway will guide the selection of agents used for cancer immunotherapy, autoimmune disorders, infection, and transplant rejection.

$299
100 tests
500 µl
This Cell Signaling Technology antibody is conjugated to APC-Cy7® and tested in-house for direct flow cytometric analysis in human cells.
APPLICATIONS
REACTIVITY
Human

Application Methods: Flow Cytometry

Background: The human leukocyte antigen (HLA) system is a gene complex encoding the major histocompatibility complex (MHC) proteins in humans. These cell surface proteins are responsible for the regulation of antigen-specific immunity in humans. HLA genes are highly polymorphic, allowing them to fine-tune the adaptive immune response. HLAs corresponding to MHC class I (HLA-A, B, and C) present small peptide antigens from inside the cell, approximately 8 to 10 amino acids in length, to CD8+ T lymphocytes in order to activate a cytotoxic T cell response. HLAs corresponding to MHC class II (HLA-DP, DM, DO, DQ, and DR) present antigens from outside of the cell, approximately 15 to 24 residues in length, to CD4+ T-helper cells, which in turn secrete cytokines and stimulate B cells to produce antibodies to that specific antigen. HLAs corresponding to MHC class III encode components of the complement system (1,2).

$139
100 tests
500 µl
This Cell Signaling Technology antibody is conjugated to FITC and tested in-house for direct flow cytometric analysis in human cells.
APPLICATIONS
REACTIVITY
Human

Application Methods: Flow Cytometry

Background: The human leukocyte antigen (HLA) system is a gene complex encoding the major histocompatibility complex (MHC) proteins in humans. These cell surface proteins are responsible for the regulation of antigen-specific immunity in humans. HLA genes are highly polymorphic, allowing them to fine-tune the adaptive immune response. HLAs corresponding to MHC class I (HLA-A, B, and C) present small peptide antigens from inside the cell, approximately 8 to 10 amino acids in length, to CD8+ T lymphocytes in order to activate a cytotoxic T cell response. HLAs corresponding to MHC class II (HLA-DP, DM, DO, DQ, and DR) present antigens from outside of the cell, approximately 15 to 24 residues in length, to CD4+ T-helper cells, which in turn secrete cytokines and stimulate B cells to produce antibodies to that specific antigen. HLAs corresponding to MHC class III encode components of the complement system (1,2).

$159
100 tests
500 µl
This Cell Signaling Technology antibody is conjugated to phycoerythrin (PE) and tested in-house for direct flow cytometric analysis in human cells.
APPLICATIONS
REACTIVITY
Human

Application Methods: Flow Cytometry

Background: The human leukocyte antigen (HLA) system is a gene complex encoding the major histocompatibility complex (MHC) proteins in humans. These cell surface proteins are responsible for the regulation of antigen-specific immunity in humans. HLA genes are highly polymorphic, allowing them to fine-tune the adaptive immune response. HLAs corresponding to MHC class I (HLA-A, B, and C) present small peptide antigens from inside the cell, approximately 8 to 10 amino acids in length, to CD8+ T lymphocytes in order to activate a cytotoxic T cell response. HLAs corresponding to MHC class II (HLA-DP, DM, DO, DQ, and DR) present antigens from outside of the cell, approximately 15 to 24 residues in length, to CD4+ T-helper cells, which in turn secrete cytokines and stimulate B cells to produce antibodies to that specific antigen. HLAs corresponding to MHC class III encode components of the complement system (1,2).

$309
100 tests
500 µl
This Cell Signaling Technology antibody is conjugated to PerCP and tested in-house for direct flow cytometric analysis in human cells.
APPLICATIONS
REACTIVITY
Human

Application Methods: Flow Cytometry

Background: The human leukocyte antigen (HLA) system is a gene complex encoding the major histocompatibility complex (MHC) proteins in humans. These cell surface proteins are responsible for the regulation of antigen-specific immunity in humans. HLA genes are highly polymorphic, allowing them to fine-tune the adaptive immune response. HLAs corresponding to MHC class I (HLA-A, B, and C) present small peptide antigens from inside the cell, approximately 8 to 10 amino acids in length, to CD8+ T lymphocytes in order to activate a cytotoxic T cell response. HLAs corresponding to MHC class II (HLA-DP, DM, DO, DQ, and DR) present antigens from outside of the cell, approximately 15 to 24 residues in length, to CD4+ T-helper cells, which in turn secrete cytokines and stimulate B cells to produce antibodies to that specific antigen. HLAs corresponding to MHC class III encode components of the complement system (1,2).

$249
100 tests
500 µl
This Cell Signaling Technology antibody is conjugated to redFluor™ 710 and tested in-house for direct flow cytometric analysis in human cells.
APPLICATIONS
REACTIVITY
Human

Application Methods: Flow Cytometry

Background: The human leukocyte antigen (HLA) system is a gene complex encoding the major histocompatibility complex (MHC) proteins in humans. These cell surface proteins are responsible for the regulation of antigen-specific immunity in humans. HLA genes are highly polymorphic, allowing them to fine-tune the adaptive immune response. HLAs corresponding to MHC class I (HLA-A, B, and C) present small peptide antigens from inside the cell, approximately 8 to 10 amino acids in length, to CD8+ T lymphocytes in order to activate a cytotoxic T cell response. HLAs corresponding to MHC class II (HLA-DP, DM, DO, DQ, and DR) present antigens from outside of the cell, approximately 15 to 24 residues in length, to CD4+ T-helper cells, which in turn secrete cytokines and stimulate B cells to produce antibodies to that specific antigen. HLAs corresponding to MHC class III encode components of the complement system (1,2).

$129
20 µl
$303
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Immunohistochemistry (Paraffin), Western Blotting

Background: HLA-G (HLA-G histocompatibility antigen, class I, G) is a non-classical MHC molecule expressed by trophoblasts in placenta, thymic epithelial cells, and some tumors. Alternative splicing leads to generation of at least six isoforms, four that are transmembrane proteins and two that are soluble (1-4). It is an inhibitory molecule involved in immune tolerance and escape, originally studied for its role in maternal tolerance of the fetus during pregnancy (1-5). HLA-G binds ILT2, ILT4, and KIR2DL4, playing a role in the regulation of natural killer, T, and monocyte/macrophage cells (4-5). Its involvement in evasion of immune response makes it a potential target for immunotherapy (6).

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Immunoprecipitation, Western Blotting

Background: HOIL-1-interacting protein (HOIP/RNF31), a RING-type E3 ubiquitin ligase, is the catalytic subunit of the Linear Ubiquitin Chain Assembly Complex (LUBAC) that is associated with TNF-R1 (1). Research studies have shown that the LUBAC consists of three subunits: HOIP, HOIL-1L, and Sharpin that facilitate canonical NF-kB activation in response to pro inflammatory cytokines through M1-linked linear ubiquitination of NEMO and RIP1 (2-6). As part of the LUBAC, HOIP has also been implicated in the negative regulation of interferon-mediated antiviral signaling through the suppression of RIG-I activation (7). The role of HOIP in LUBAC function and human disease is underscored by naturally occurring mutations in HOIP that impair LUBAC assembly and NF-kb activation. Patients that are homozygous for this mutation in HOIP have multi organ auto inflammation and immunodeficiency (8).

$293
100 µl
APPLICATIONS
REACTIVITY
Mouse, Rat

Application Methods: Flow Cytometry, Immunofluorescence (Frozen), Immunofluorescence (Immunocytochemistry), Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blotting

Background: HS1 (HCLS1, LckBP1, p75) is a protein kinase substrate that is expressed only in tissues and cells of hematopoietic origin (1,2). HS1 contains four cortactin repeats and a single SH3 domain (2). This intracellular protein is phosphorylated following immune receptor activation, which promotes recruitment of HS1 to the immune synapse (3-5). Phosphorylation of HS1 is required to regulate actin dynamics and provide docking sites for many other signaling molecules, such as Vav1 and PLCγ1 (6). HS1 also plays an important role in platelet activation (7).

$293
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Flow Cytometry, Immunofluorescence (Immunocytochemistry), Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blotting

Background: HS1 (HCLS1, LckBP1, p75) is a protein kinase substrate that is expressed only in tissues and cells of hematopoietic origin (1,2). HS1 contains four cortactin repeats and a single SH3 domain (2). This intracellular protein is phosphorylated following immune receptor activation, which promotes recruitment of HS1 to the immune synapse (3-5). Phosphorylation of HS1 is required to regulate actin dynamics and provide docking sites for many other signaling molecules, such as Vav1 and PLCγ1 (6). HS1 also plays an important role in platelet activation (7).

$345
100 µg
Neutralizing antibodies can be used to inhibit normal biological function through their binding to biological molecules. These reagents can be used to determine the effects that a particular molecule has in biological systems. Human EGF Neutralizing (D8A1) Rabbit mAb has been shown to neutralize the EGF-induced proliferation of MCF 10A cells in vitro with an ND50 in the range of 200-700 ng/ml.
REACTIVITY
Human
$345
100 µg
Neutralizing antibodies can be used to inhibit normal biological function through their binding to biological molecules. These reagents can be used to determine the effects that a particular molecule has in biological systems. Human IL-17A Neutralizing (D13C2) Rabbit mAb has been shown to neutralize the production of IL-6 from human dermal fibroblast cells in vitro with an ND50 in the range of 8-50 ng/ml.
REACTIVITY
Human
$345
100 µg
Neutralizing antibodies can be used to inhibit normal biological function through their binding to biological molecules. These reagents can be used to determine the effects that a particular molecule has in biological systems. Human IL-4 Neutralizing (D20H1) Rabbit mAb has been shown to neutralize the proliferation of TF-1 cells in vitro with an ND50 in the range of 3-19 ng/ml.
REACTIVITY
Human
$345
100 µg
Neutralizing antibodies can be used to inhibit normal biological function through their binding to biological molecules. These reagents can be used to determine the effects that a particular molecule has in biological systems. TNF-α has known functions of cell cytotoxicity, cell activation, and apoptosis in different cell types. Human TNF-α Neutralizing (D1B4) Rabbit mAb has been shown to neutralize the cytotoxic effects of TNF-α in L-929 mouse fibroblast cells. Utilizing 1 ng/ml of hTNF-α #8902 and 1 µg/ml of actinomycin D, Human TNF-α Neutralizing (D1B4) Rabbit mAb rescued L-929 cells with an ND50 in the range of 4-12 ng/ml.
REACTIVITY
Human

Background: TNF-α, the prototypical member of the TNF protein superfamily, is a homotrimeric type-II membrane protein (1,2). Membrane-bound TNF-α is cleaved by the metalloprotease TACE/ADAM17 to generate a soluble homotrimer (2). Both membrane and soluble forms of TNF-α are biologically active. TNF-α is produced by a variety of immune cells including T cells, B cells, NK cells, and macrophages (1). Cellular response to TNF-α is mediated through interaction with receptors TNF-R1 and TNF-R2 and results in activation of pathways that favor both cell survival and apoptosis depending on the cell type and biological context. Activation of kinase pathways (including JNK, Erk1/2, p38 MAPK, and NF-κB) promotes the survival of cells, while TNF-α-mediated activation of caspase-8 leads to programmed cell death (1,2). TNF-α plays a key regulatory role in inflammation and host defense against bacterial infection, notably Mycobacterium tuberculosis (3).

$269
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: IHC-Leica® Bond™, Immunohistochemistry (Paraffin)

Background: ICOS (Inducible Co-Stimulator, CD278) is a member of the CD28 family that regulates T cell activity and immune responses (1). The ICOS protein contains an extracellular IgV like domain, a transmembrane domain, and an intracellular domain with a YMFM motif (1-2). ICOS is primarily expressed on activated CD4+ and CD8+ T cells (1). Upon binding to its ligand, ICOS potentiates the T cell response to antigen through activation of the PI3K signaling pathway (2). In addition to enhancing T cell activation and proliferation, ICOS plays an important role in the regulation of T follicular helper cells (4). Research studies suggest that ICOS is a potential therapeutic target, and could serve as a prognostic biomarker for neoplastic therapy involving CTLA-4 blockade (5-7).

$305
50 tests
100 µl
This Cell Signaling Technology antibody is conjugated to phycoerythrin (PE) and tested in-house for direct flow cytometry analysis in human cells. This antibody is expected to exhibit the same species cross-reactivity as the unconjugated IDO (D5J4E™) Rabbit mAb #86630.
APPLICATIONS
REACTIVITY
Human

Application Methods: Flow Cytometry

Background: INDO/IDO1/indoleamine 2,3-dioxygenase (IDO) is an IFN-γ-inducible enzyme that catalyzes the rate-limiting step of tryptophan degradation (1). IDO is upregulated in many tumors and in dendritic cells in tumor-draining lymph nodes. Elevated tryptophan catabolism in these cells leads to tryptophan starvation of T cells, limiting T cell proliferation and activation (2). Therefore, IDO is considered an immunosuppresive molecule, and research studies have shown that upregulation of IDO is a mechanism of cancer immune evasion (3). The gastrointestinal stromal tumor drug, imatinib, was found to act, in part, by reducing IDO expression, resulting in increased CD8+ T cell activation and induction of apoptosis in regulatory T cells (4). In addition to its enzymatic activity, IDO was recently shown to have signaling capability through an immunoreceptor tyrosine-based inhibitory motif (ITIM) that is phosphorylated by Fyn in response to TGF-β. This leads to recruitment of SHP-1 and activation of the noncanonical NF-κB pathway (5).

$269
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Flow Cytometry, IHC-Leica® Bond™, Immunofluorescence (Immunocytochemistry), Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blotting

Background: INDO/IDO1/indoleamine 2,3-dioxygenase (IDO) is an IFN-γ-inducible enzyme that catalyzes the rate-limiting step of tryptophan degradation (1). IDO is upregulated in many tumors and in dendritic cells in tumor-draining lymph nodes. Elevated tryptophan catabolism in these cells leads to tryptophan starvation of T cells, limiting T cell proliferation and activation (2). Therefore, IDO is considered an immunosuppresive molecule, and research studies have shown that upregulation of IDO is a mechanism of cancer immune evasion (3). The gastrointestinal stromal tumor drug, imatinib, was found to act, in part, by reducing IDO expression, resulting in increased CD8+ T cell activation and induction of apoptosis in regulatory T cells (4). In addition to its enzymatic activity, IDO was recently shown to have signaling capability through an immunoreceptor tyrosine-based inhibitory motif (ITIM) that is phosphorylated by Fyn in response to TGF-β. This leads to recruitment of SHP-1 and activation of the noncanonical NF-κB pathway (5).

$260
100 µl
APPLICATIONS
REACTIVITY
Mouse

Application Methods: Flow Cytometry, Immunoprecipitation, Western Blotting

Background: INDO/IDO1/indoleamine 2,3-dioxygenase (IDO) is an IFN-γ-inducible enzyme that catalyzes the rate-limiting step of tryptophan degradation (1). IDO is upregulated in many tumors and in dendritic cells in tumor-draining lymph nodes. Elevated tryptophan catabolism in these cells leads to tryptophan starvation of T cells, limiting T cell proliferation and activation (2). Therefore, IDO is considered an immunosuppresive molecule, and research studies have shown that upregulation of IDO is a mechanism of cancer immune evasion (3). The gastrointestinal stromal tumor drug, imatinib, was found to act, in part, by reducing IDO expression, resulting in increased CD8+ T cell activation and induction of apoptosis in regulatory T cells (4). In addition to its enzymatic activity, IDO was recently shown to have signaling capability through an immunoreceptor tyrosine-based inhibitory motif (ITIM) that is phosphorylated by Fyn in response to TGF-β. This leads to recruitment of SHP-1 and activation of the noncanonical NF-κB pathway (5).

$260
100 µl
APPLICATIONS
REACTIVITY
Mouse

Application Methods: Immunofluorescence (Immunocytochemistry), Immunoprecipitation, Western Blotting

Background: INDO/IDO1/indoleamine 2,3-dioxygenase (IDO) is an IFN-γ-inducible enzyme that catalyzes the rate-limiting step of tryptophan degradation (1). IDO is upregulated in many tumors and in dendritic cells in tumor-draining lymph nodes. Elevated tryptophan catabolism in these cells leads to tryptophan starvation of T cells, limiting T cell proliferation and activation (2). Therefore, IDO is considered an immunosuppresive molecule, and research studies have shown that upregulation of IDO is a mechanism of cancer immune evasion (3). The gastrointestinal stromal tumor drug, imatinib, was found to act, in part, by reducing IDO expression, resulting in increased CD8+ T cell activation and induction of apoptosis in regulatory T cells (4). In addition to its enzymatic activity, IDO was recently shown to have signaling capability through an immunoreceptor tyrosine-based inhibitory motif (ITIM) that is phosphorylated by Fyn in response to TGF-β. This leads to recruitment of SHP-1 and activation of the noncanonical NF-κB pathway (5).

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blotting

Background: IFI16 belongs to the PYHIN family, which consists of four members in humans (Aim2, IFIX, MNDA, and IFI16) and at least thirteen members in mice (1). The closest homolog of IFI16 in mice is p204. The PYHIN family is characterized by the presence of one or two HIN-200 domains that bind double stranded DNA and a PYRIN domain that mediates interactions among family members, as well as the inflammasome-forming ASC protein (1). IFI16 also has a nuclear localization signal, but has been observed to bind DNA in both the cytoplasm and nucleus (2,3). There are three isoforms of IFI16 produced by alternative splicing (4). IFI16 is constitutively expressed by some cells, such as lymphocytes, and highly inducible in many others by interferons (5). IFI16 has been shown to directly interact with p53 and to play a role in cellular senescence by modulating p53 activity (6). IFI16 was shown to directly sense intracellular viral DNA, leading to recruitment of STING and activation of IRF-3 and NF-κB (2). Investigators have observed increased levels of IFI16 and anti-IFI16 autoantibodies in patients with systemic lupus erythematosus (7-9).

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: IHC-Leica® Bond™, Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blotting

Background: IFIT1 (interferon-induced protein with tetratricopeptide repeats 1) belongs to the IFIT family of proteins, which consists of four members in humans (IFIT1, IFIT2, IFIT3, and IFIT5) and three members in mice (IFIT1, IFIT2, and IFIT3) (1). IFIT1 expression is induced by Type I Interferons resulting from viral infection (2). IFIT1 is an antiviral protein that directly binds viral RNA that has a 5’ triphosphate group (PPP-RNA) (2). In humans, the viral PPP-RNA bound IFIT1 forms a complex with IFIT2 and IFIT3 to sequester the viral PPP-RNA and prevent replication (2). IFIT1 has also been shown to inhibit translation by binding to the eukaryotic initiation factor-3 (eIF-3) (3).

$111
20 µl
$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blotting

Background: Interferon-induced transmembrane protein (IFITM) family members are composed of short amino- and carboxy-termini, two transmembrane domains, and a cytoplasmic domain (1). There are four family members in humans: IFITM1, IFITM2, IFITM3, and IFITM5 (2,3). Mice have two additional family members, IFITM6 and IFITM7 (2,3). Basal expression of IFITM proteins is observed in some cells and expression can also be induced by type I and type II interferons (4-6). The primary function of IFITM family proteins appears to be viral restriction, as IFITM proteins inhibit cytosolic entry of viruses by preventing fusion of viral and host membranes (7,8). The mechanism by which IFITM proteins inhibit fusion is unclear. Although IFITM proteins are present on both the plasma membrane and intracellular membranes, they most effectively restrict viral fusion in late endosomes and lysosomes (8,9). In addition, different family members exhibit specific viral preferences (9). For example, IFITM3 is most effective at restricting influenza A infection, while IFITM1 is more successful in controlling filoviruses and SARS (9,10).

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Western Blotting

Background: Interferons (IFNs) appear both locally and systematically early after viral infection and participate in limiting the spread of infection. They also affect cell differentiation, growth, surface antigen expression and immunoregulation (1). There are three naturally occurring interferons: α, β and γ. IFN-α is derived from lymphoblastic tissue and has a number of therapeutic applications in the treatment of various human cancers and diseases of viral origin. Recombinant IFN-α from both natural and synthetic genes binds to a common cell surface receptor and induces antiviral activity in a variety of cell lines. When binding to discrete cell surface receptors on target cells, IFN-α induces rapid changes in Jak/Stat phosphorylation, which initiates the Jak/Stat signaling pathway (2). IFN-α signaling also involves production of DAG without an increased intracellular free calcium concentration and the subsequent activation of calcium-independent isoforms of PKC (β and ε) (3). All IFN-α signaling pathways lead to final alterations of gene expression, which mediate their pleiotropic biologic activities.

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Western Blotting

Background: Interferons (IFNs) appear both locally and systematically early after viral infection and participate in limiting the spread of infection. They also affect cell differentiation, growth, surface antigen expression and immunoregulation (1). There are three naturally occurring interferons: α, β and γ. IFN-α is derived from lymphoblastic tissue and has a number of therapeutic applications in the treatment of various human cancers and diseases of viral origin. Recombinant IFN-α from both natural and synthetic genes binds to a common cell surface receptor and induces antiviral activity in a variety of cell lines. When binding to discrete cell surface receptors on target cells, IFN-α induces rapid changes in Jak/Stat phosphorylation, which initiates the Jak/Stat signaling pathway (2). IFN-α signaling also involves production of DAG without an increased intracellular free calcium concentration and the subsequent activation of calcium-independent isoforms of PKC (β and ε) (3). All IFN-α signaling pathways lead to final alterations of gene expression, which mediate their pleiotropic biologic activities.

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Western Blotting

Background: The type I interferon (IFN) family includes IFN-β1 and IFN-α1 through IFN-α13 in humans and IFN-α1 through IFN-α14 in mice. Type I IFN is produced following detection of pathogen-associated molecular patterns (PAMPs) and is important for induction of antiviral genes, activation of dendritic cells, and initiation of adaptive immunity (1, 2). Type I IFNs signal through the IFN alpha receptor (IFNAR), which is a heterodimer composed of IFNAR1 and IFNAR2. Activation of IFNAR leads to formation of the nuclear complex IFN-stimulated gene factor 3 (ISGF3), which consists of STAT1, STAT2, and IRF-9 (3, 4). ISGF3 binds to IFN-stimulated response elements (ISREs) to initiate transcription of interferon-stimulated genes (3).